BioMarin Pharmaceutical | BMRN - 债务



金融业
股票价格
USD
资产
USD 11.72B
现金及等价物
USD 874.01M
销售成本
USD 276.29M
流动资产
USD 3.97B
流动负债
USD 1.66B
债务
USD 1.44B
EBIT
USD 105.61M
EBITDA
USD 146.05M
员工
3.04K
EPS每股收益
USD 1.2
股本和储备
USD 6.32B
销售毛利
USD 713.42M
债务利息支出
USD 63.3M
利息收入
USD 22.56M
贷款资金
USD 3.53B
市值
USD 11.6B
净收入
USD 44.76M
营业费用
USD 6.32B
营业利润
USD 105.61M
普通股股本
USD 193.54M
PE价格收益
21.07
税前利润
USD 141.2M
销售收入
USD 990M
销售和管理费用
USD 395.55M
股票
USD 1.78B
贸易债权人
USD 913.67M
应收帐款人
USD 1.06B


债务 更改 日
Acadia Pharmaceuticals USD 50.79M 1.39M 2026-03
Agios Pharmaceuticals USD 35.74M 4.46M 2026-03
Alnylam Pharmaceuticals USD 1.27B 5.33M 2026-03
Amgen USD 57.32B 2.72B 2026-03
Bayer EUR 36.45B 2.93B 2025-12
Biogen USD 8.09B 1.53B 2026-06
BioMarin Pharmaceutical USD 1.44B 833.74M 2026-03
Gilead Sciences USD 22.17B 2.76B 2026-03
Incyte USD 38.27M 1.16M 2026-06
Insmed USD 725.8M 1.82M 2026-06
Ionis Pharmaceuticals USD 1.91B 425.5M 2026-06
Moderna USD 1.3B 7M 2026-03
Neurocrine Biosciences USD 406.2M 9.1M 2026-03
PTC Therapeutics USD 286.94M 2.42B 2026-03
Puma Biotechnology USD 89.06M 55.07M 2024-06
Regeneron Pharmaceuticals USD 2.71B 400K 2026-06
Roche Holding CHF 33.03B 1.41B 2025-06
Sangamo BioSciences USD 0 0 2022-06
Sanofi EUR 20.02B 1.73B 2026-03
Sarepta Therapeutics USD 1.04B 3.08M 2026-03
Ultragenyx Pharmaceutical USD 36M 2.17M 2025-12
United Therapeutics USD 200M 100M 2025-03
Vertex Pharmaceuticals USD 1.98B 8.9M 2026-06